Showing results (171-180 of 317) with videos related to

Sort By:
Pageof 32
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2009
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT studyE Van Cutsem, F Rivera, S Berry, et al.
Acta Gastro-Enterologica Belgica|July 15, 2005
Report on the Belgian consensus meeting on colorectal cancer screeningM Adler, M De Vos, A Dufour, et al.
Lancet (London, England)|November 10, 1998
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerP Rougier, E Van Cutsem, E Bajetta, et al.
AIDS and Behavior|September 17, 2024
Profile of Persons Recently Infected with HIV-1 in Belgium: New Insights to Tailor Prevention EffortsC Vanden Bulcke, J Deblonde, C Necsoi, et al.
Oncology|February 17, 2005
Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II studyJ-L Van Laethem, Ph Van Maele, C Verslype, et al.
Acta Cardiologica|February 15, 2000
Structural heart adaptations in triathletesC Claessens, P Claessens, H Bloemen, et al.
British Journal of Cancer|May 20, 2015
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancerT Macarulla, A Cervantes, J Tabernero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 27, 2013
Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive OncologyI Borbath, A Ceratti, C Verslype, et al.
British Journal of Cancer|April 14, 2015
Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trialM Verstraete, A Debucquoy, J Dekervel, et al.
Oncogene|December 22, 1999
Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor)S Tejpar, F Nollet, C Li, et al.
Pageof 32